Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT00289640 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: ipilimumab (MDX-010, BMS-734016)
DRUG: Ipilimumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]